Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNMT1 | P26358 | 3/20 | 0.66 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.66 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 5/20 | 0.62 |
| ▸ | THRB | P10828 | 1/20 | 0.62 |
| ▸ | MTOR | P42345 | 1/20 | 0.62 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.62 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.62 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.62 |
| ▸ | PDE3A | Q14432 | 4/20 | 0.59 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.59 |
| ▸ | ALB | P02768 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.59 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.59 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.59 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.58 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.58 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.51 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Doxecitine SCHEMBL29910618 | 1.00 | DNMT1 (0.66) | DNMT1ADRB1POLBLMNATHRB | |
| Doxecitine SCHEMBL30616799 | 1.00 | DNMT1 (0.66) | DNMT1ADRB1POLBLMNATHRB | |
| Doxecitine SCHEMBL15832461 | 1.00 | DNMT1 (0.66) | DNMT1ADRB1POLBLMNATHRB | |
| Doxecitine SCHEMBL887491 | 1.00 | DNMT1 (0.66) | DNMT1ADRB1POLBLMNATHRB | |
| Doxecitine SCHEMBL10238960 | 1.00 | DNMT1 (0.66) | DNMT1ADRB1POLBLMNATHRB | |
| Doxecitine SCHEMBL31503186 | 1.00 | DNMT1 (0.66) | DNMT1ADRB1POLBLMNATHRB | |
| Doxecitine SCHEMBL13700553 | 1.00 | DNMT1 (0.66) | DNMT1ADRB1POLBLMNATHRB | |
| Doxecitine SCHEMBL23178 | 1.00 | DNMT1 (0.66) | DNMT1ADRB1POLBLMNATHRB | |
| Doxecitine SCHEMBL193815 | 1.00 | DNMT1 (0.66) | DNMT1ADRB1POLBLMNATHRB | |
| Doxecitine SCHEMBL2623809 | 1.00 | DNMT1 (0.66) | DNMT1ADRB1POLBLMNATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024129985-A2 | ANTIVIRAL COMPOUNDS, COMPOSITIONS, AND USES THEREOF | Lakewood Amedex, Inc. (US) | 2024-06-20 | — | — | WO | disclosed |
| WO-2023187599-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES | DIDENKO KIRILL (MX) | 2023-10-05 | — | — | WO | disclosed |
| EP-4181908-A2 | COMPOSITIONS COMPRISING GARDOS CHANNEL ANTAGONISTS AND THEIR USES | Adimabio LLC (US) | 2023-05-24 | — | — | EP | disclosed |
| EP-3987027-A1 | ENDONUCLEASE-RESISTANT MESSENGER RNA AND USES THEREOF | ModernaTX, Inc. (US) | 2022-04-27 | — | — | EP | disclosed |
| US-20210139522-A1 | ANTIMICROBIAL COMPOUNDS, COMPOSITIONS, AND USES THEREOF | Lakewood Amedex, Inc. | 2021-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210139522-A1 | ANTIMICROBIAL COMPOUNDS, COMPOSITIONS, AND USES THEREOF | CFTR, ABCB11, CEL | DNMT1 4834/4885ADRB1 2832/4885POLB 2770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.